Literature DB >> 18514987

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Francesca Tentori1, Margaret J Blayney, Justin M Albert, Brenda W Gillespie, Peter G Kerr, Jürgen Bommer, Eric W Young, Tadao Akizawa, Takashi Akiba, Ronald L Pisoni, Bruce M Robinson, Friedrich K Port.   

Abstract

BACKGROUND: Abnormalities in serum calcium, phosphorus, and parathyroid hormone (PTH) concentrations are common in patients with chronic kidney disease and have been associated with increased morbidity and mortality. No clinical trials have been conducted to clearly identify categories of calcium, phosphorus, and PTH levels associated with the lowest mortality risk. Current clinical practice guidelines are based largely on expert opinions, and clinically relevant differences exist among guidelines across countries. We sought to describe international trends in calcium, phosphorus, and PTH levels during 10 years and identify mortality risk categories in the Dialysis Outcomes and Practice Patterns Study (DOPPS), an international study of hemodialysis practices and associated outcomes. STUDY
DESIGN: Prospective cohort study. PARTICIPANTS: 25,588 patients with end-stage renal disease on hemodialysis therapy for longer than 180 days at 925 facilities in DOPPS I (1996-2001), DOPPS II (2002-2004), or DOPPS III (2005-2007). PREDICTORS: Serum calcium, albumin-corrected calcium (Ca(Alb)), phosphorus, and PTH levels. OUTCOMES: Adjusted hazard ratios for all-cause and cardiovascular mortality calculated using Cox models.
RESULTS: Distributions of mineral metabolism markers differed across DOPPS countries and phases, with lower calcium and phosphorus levels observed in the most recent phase of DOPPS. Survival models identified categories with the lowest mortality risk for calcium (8.6 to 10.0 mg/dL), Ca(Alb) (7.6 to 9.5 mg/dL), phosphorus (3.6 to 5.0 mg/dL), and PTH (101 to 300 pg/mL). The greatest risk of mortality was found for calcium or Ca(Alb) levels greater than 10.0 mg/dL, phosphorus levels greater than 7.0 mg/dL, and PTH levels greater than 600 pg/mL and in patients with combinations of high-risk categories of calcium, phosphorus, and PTH. LIMITATIONS: Because of the observational nature of DOPPS, this study can only indicate an association between mineral metabolism categories and mortality.
CONCLUSIONS: Our results provide important information about mineral metabolism trends in hemodialysis patients in 12 countries during a decade. The risk categories identified in the DOPPS cohort may be relevant to efforts at international harmonization of existing clinical guidelines for mineral metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514987     DOI: 10.1053/j.ajkd.2008.03.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  320 in total

Review 1.  Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Chun-Juan Zhai; Xiao-Wei Yang; Jing Sun; Rong Wang
Journal:  Int Urol Nephrol       Date:  2014-11-16       Impact factor: 2.370

2.  Can dialysis modality influence cardiovascular outcome?

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2012-06-03       Impact factor: 3.714

3.  Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.

Authors:  Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2010-09-03       Impact factor: 3.754

4.  Association of pretransplant serum phosphorus with posttransplant outcomes.

Authors:  Marcelo S Sampaio; Miklos Z Molnar; Csaba P Kovesdy; Rajnish Mehrotra; Istvan Mucsi; John J Sim; Mahesh Krishnan; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-29       Impact factor: 8.237

5.  Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.

Authors:  Tadao Akizawa; Ryo Kido; Masafumi Fukagawa; Yoshihiro Onishi; Takuhiro Yamaguchi; Takeshi Hasegawa; Shunichi Fukuhara; Kiyoshi Kurokawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

6.  Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Authors:  Hirotaka Komaba; Mia Wang; Masatomo Taniguchi; Suguru Yamamoto; Takanobu Nomura; Douglas E Schaubel; Abigail R Smith; Jarcy Zee; Angelo Karaboyas; Brian Bieber; Masafumi Fukagawa; Francesca Tentori
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 8.237

7.  Can cardiac troponin T level be used to predict survival of patients awaiting renal transplantation?

Authors:  Martha Pavlakis
Journal:  Nat Clin Pract Nephrol       Date:  2009-01-27

8.  Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.

Authors:  Melissa Soohoo; Mingliang Feng; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Wei Ling Lau; Jialin Wang; Vanessa A Ravel; Steven Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2016-03-08       Impact factor: 3.754

9.  Cinacalcet may improve oxidative DNA damage in maintenance hemodialysis patients: an observational study.

Authors:  Elif Ari; Yuksel Kaya; Halit Demir; Ebru Asicioglu; Zehra Eren; Eray Celik; Hakki Arikan
Journal:  Int Urol Nephrol       Date:  2014-05-09       Impact factor: 2.370

10.  Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.

Authors:  Ebele M Umeukeje; Joseph R Merighi; Teri Browne; Jacquelyn N Victoroff; Kausik Umanath; Julia B Lewis; T Alp Ikizler; Kenneth A Wallston; Kerri Cavanaugh
Journal:  J Ren Nutr       Date:  2015-04-22       Impact factor: 3.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.